Stay updated with breaking news from Dan Budwick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing...
SAN FRANCISCO, Calif. and WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of
CAMBRIDGE, Mass., Feb. 28, 2024 -- Beam Therapeutics Inc. , a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in...
CAMBRIDGE, Mass., Feb. 28, 2024 -- Prime Medicine, Inc. , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that...
WALTHAM, Mass., Feb. 28, 2024 -- Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with...